TriangleAtezolizumab (NCT05019703)
Atezolizumab trial for Locally Advanced Osteosarcoma (NCT05019703). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged twelve or older with metastatic or unresectable osteosarcoma that returned or resisted conventional chemotherapy. Prior cabozantinib or checkpoint therapy combined with a VEGF-targeted kinase inhibitor is excluded.
The idea: combine atezolizumab infusions every three weeks with daily oral cabozantinib. Atezolizumab blocks PD-L1 to support immune attack; cabozantinib blocks signals involved in tumor growth and blood-vessel formation. Researchers measure time before progression or death. Tumor tissue is required, sometimes through a new biopsy.
This phase 2 study plans 40 patients. John Livingston leads two recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.